Role of Secretoglobin 1A1 Protein in COVID-19-induced Thrombosis

分泌球蛋白 1A1 蛋白在 COVID-19 诱导的血栓形成中的作用

基本信息

  • 批准号:
    10255855
  • 负责人:
  • 金额:
    $ 25.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

Severe COVID-19 infection causes coagulopathies leading to stroke, pulmonary embolism, DVT, and disseminated intravascular coagulation (DIC). These complications of COVID-19 infection are often lethal and can lead to permanent disability in survivors. COVID-19-induced coagulopathy is atypical of most respiratory viral infections and it is important to understand the basis for these effects. Secretoglobin 1A1 (SCGB1A1, also known as CC10, CC16, CCSP, and uteroglobin) is a small globular immunomodulatory protein that is highly expressed in normal lungs by Club cells. Club cells are injured during COVID-19 infection, by the extreme inflammatory response and/or by direct viral infection. Club cell depletion results in SCGB1A1 deficiency. SCGB1A1 is important not only in maintaining lung homeostasis, function, and repair, but also circulates in the blood where it likely has additional homeostatic functions. SCGB1A1 is known to inhibit platelet aggregation and Factor XIIIa transglutaminase activity in vitro and may therefore play a role in vascular and/or blood homeostasis particularly as relates to balancing coagulation responses. SCGB1A1 is also known to be chemically modified by exposure to reactive oxygen and nitrogen species (ROS/RNS) during severe inflammatory responses in the lungs and the impact of these modifications on the anti-thrombotic activities of SCGB1A1 merits investigation. The proposed research will investigate the effects of ROS/RNS modification of SCGB1A1 on coagulation and clot formation in vitro, as well as in an animal model, and then will evaluate the potential depletion of SCGB1A1 and ROS/RNS-mediated modifications of native SCGB1A1 in COVID-19 patients and the potentiation of thrombosis in COVID-19 patients.
严重的COVID-19感染会导致凝血功能障碍,导致中风、肺栓塞、DVT, 和弥散性血管内凝血(DIC)。COVID-19感染的这些并发症 往往是致命的,并可能导致幸存者终身残疾。COVID-19诱导 凝血病是大多数呼吸道病毒感染的非典型性疾病, 这些影响的基础。分泌珠蛋白1A 1(SCGB 1A 1,也称为CC 10、CC 16、CCSP和CC 18)是一种免疫球蛋白。 子宫珠蛋白)是一种小的球状免疫调节蛋白,在正常子宫中高度表达。 俱乐部细胞的肺。在COVID-19感染期间,俱乐部细胞受到了极大的损伤, 炎症反应和/或直接病毒感染。俱乐部细胞耗竭导致SCGB 1A 1 缺陷SCGB 1A 1不仅在维持肺的稳态、功能和修复方面很重要, 而且还在血液中循环,在那里它可能具有额外的稳态功能。SCGB 1A 1是 已知在体外抑制血小板聚集和因子XIIIa转氨酶活性,并可 因此在血管和/或血液稳态中起作用 凝血反应还已知SCGB 1A 1通过暴露于 活性氧和氮(ROS/RNS)在严重炎症反应中的作用 肺以及这些修饰对SCGB 1A 1优点抗血栓活性的影响 调查该研究将探讨ROS/RNS修饰对细胞增殖的影响。 SCGB 1A 1在体外以及在动物模型中对凝血和凝块形成的影响,然后将 评估SCGB 1A 1的潜在消耗和ROS/RNS介导的天然细胞的修饰, COVID-19患者中的SCGB 1A 1和COVID-19患者中血栓形成的增强。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

APRILE L PILON其他文献

APRILE L PILON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('APRILE L PILON', 18)}}的其他基金

Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction
重组人 CC10 蛋白用于治疗和预防慢性同种异体肺移植功能障碍
  • 批准号:
    10602077
  • 财政年份:
    2023
  • 资助金额:
    $ 25.65万
  • 项目类别:
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept
开发用于快速、经济生产肽的新型生物工艺平台
  • 批准号:
    7325568
  • 财政年份:
    2007
  • 资助金额:
    $ 25.65万
  • 项目类别:
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept
开发用于快速、经济生产肽的新型生物工艺平台
  • 批准号:
    7848987
  • 财政年份:
    2007
  • 资助金额:
    $ 25.65万
  • 项目类别:
Recombinant CC10 for treatment of meconium aspiration
重组 CC10 用于治疗胎便误吸
  • 批准号:
    6645573
  • 财政年份:
    2003
  • 资助金额:
    $ 25.65万
  • 项目类别:
Optimum Dose of rhCC10 for Lung Protection in IRDS
rhCC10 保护 IRDS 肺部的最佳剂量
  • 批准号:
    6344251
  • 财政年份:
    2001
  • 资助金额:
    $ 25.65万
  • 项目类别:
RECOMBINANT HUMAN CC10 AND NOTCH-1 ANTAGONIST IN NSCLC
非小细胞肺癌 (NSCLC) 中的重组人类 CC10 和 NOTCH-1 拮抗剂
  • 批准号:
    6143475
  • 财政年份:
    2000
  • 资助金额:
    $ 25.65万
  • 项目类别:
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD
用于预防新生儿 BPD 的重组人 CC10
  • 批准号:
    2616435
  • 财政年份:
    1998
  • 资助金额:
    $ 25.65万
  • 项目类别:
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD
用于预防新生儿 BPD 的重组人 CC10
  • 批准号:
    6017162
  • 财政年份:
    1998
  • 资助金额:
    $ 25.65万
  • 项目类别:
UBIQUITIN FUSION FOR PEPTIDE IMMUNE DISPLAY AND VACCINES
用于肽免疫展示和疫苗的泛素融合
  • 批准号:
    2076869
  • 财政年份:
    1996
  • 资助金额:
    $ 25.65万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.65万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.65万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.65万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 25.65万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 25.65万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 25.65万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 25.65万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 25.65万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 25.65万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 25.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了